ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCRX vs ADMA // GROSS PROFIT MARGIN

BioCryst Pharmaceuticals Inc. (NASDAQ) VS. ADMA Biologics Inc (NASDAQ) • 15-METRIC TALLY: BCRX 4 — ADMA 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. ADMA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCRX ADMA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 57.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% 32.90% +52.10 BCRX /roic <GO>
EV/EBITDA & P/E Valuation 6.1x 12.4x -6.30 BCRX /valuation <GO>
Free Cash Flow Yield 15.96% 1.06% +14.90 BCRX /fcf-yield <GO>
Operating Margin — 37.50% — TIE /operating-margins <GO>
Net Profit Margin — 28.80% — TIE /net-margins <GO>
Revenue Growth (YoY) — 19.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 12.98 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 ADMA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.8 54.6 -5.80 ADMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 7.7x 15.0x -7.30 BCRX /forward-pe <GO>
Enterprise Scale & Market Cap $2.11B $2.48B -$370.4M ADMA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCRX REV ADMA REV BCRX GROSS % ADMA GROSS % BCRX FCF ADMA FCF
FY 2025 $954.8M $510.2M — 57.4% $347.4M $27.8M
FY 2024 $7.1M $426.5M — 51.5% -$52.0M $110.4M
FY 2023 $290.4M $258.2M — — -$95.1M $8.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
ADMA // BETA —